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Abstract
Cardiac death remains one of the leading causes of mortality worldwide. Recent research
has shed light on pathophysiological mechanisms underlying cardiac death, and several
genetic variants in novel candidate genes have been identified as risk factors. However, the
vast majority of studies performed so far investigated genetic associations with specific
forms of cardiac death only (sudden, arrhythmogenic, ischemic etc.). The aim of the present
investigation was to find a genetic marker that can be used as a general, powerful predictor
of cardiac death risk. To this end, a case-control association study was performed on a het-
erogeneous cohort of cardiac death victims (n=360) and age-matched controls (n=300).
Five single nucleotide polymorphisms (SNPs) from five candidate genes (beta2 adrenergic
receptor, nitric oxide synthase 1 adaptor protein, ryanodine receptor 2, sodium channel
type V alpha subunit and transforming growth factor-beta receptor 2) that had previously
been shown to associate with certain forms of cardiac death were genotyped using
sequence-specific real-time PCR probes. Logistic regression analysis revealed that the CC
genotype of the rs11720524 polymorphism in the SCN5A gene encoding a subunit of the
cardiac voltage-gated sodium channel occurred more frequently in the highly heteroge-
neous cardiac death cohort compared to the control population (p=0.019, odds ratio:
1.351). A detailed subgroup analysis uncovered that this effect was due to an association of
this variant with cardiac death in chronic ischemic heart disease (p=0.012, odds ratio =
1.455). None of the other investigated polymorphisms showed association with cardiac
death in this context. In conclusion, our results shed light on the role of this non-coding poly-
morphism in cardiac death in ischemic cardiomyopathy. Functional studies are needed to
explore the pathophysiological background of this association.
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Introduction
Though the past decades have seen a rapid development in the field of therapeutic options,
sudden cardiac death (SCD) still remains a leading cause of mortality worldwide [1]. The
underlying pathological processes—acute or chronic heart failure—might be elicited by numer-
ous factors including coronary artery disease, hypertension, valvular dysfunctions, primary
cardiomyopathy, inflammatory diseases as well as arrhythmias. In patients above 50 years of
age, coronary heart disease and concomitant chronic ischemic cardiomyopathy account for
75–80% of SCD cases [2]. Persistent myocardial ischemia might elicit ventricular tachyarrhyt-
mias via several mechanisms [3]. On the one hand, myocardial hypoxia is a potent arrhythmo-
genic factor that impairs ionic homeostasis by blocking ion pumps and thereby interferes with
cardiac ion channel conductance in the plasma membrane [3]. Moreover, the emergence of
arrhythmogenic foci in myocardial remodeling compromises the electrical activity of the heart,
playing a causative role in the occurrence of fatal arrhythmias that underlie sudden decompen-
sation and cardiac death [4, 5]. Genetic markers governing structural remodeling include a
large body of genetic variants that impair force generation, calcium cycling and transcriptional
regulation of cardiac gene expression [6] as well as perturbed expression of regulatory micro-
RNAs [7].
Recently, numerous genetic studies have been conducted to identify candidate genes whose
mutations and polymorphisms are associated with increased cardiovascular risk in general and
sudden cardiac death in particular. Notably, these prospective investigations have shed light on
the seminal role of rare and common variants of genes encoding cardiac voltage-gated ion
channels, plasma membrane receptors and intracellular signaling proteins [8–11].
As far as channelopathies are concerned, the SCN5A gene encoding the α subunit of the car-
diac voltage-gated sodium channel (Nav1.5) might harbor several mutations associated with
arrhythmia vulnerability syndromes including the Brugada syndrome [12], sick sinus syn-
drome [13], the arrhythmogenic long QT syndrome [14] and susceptibility to ventricular fibril-
lation during myocardial infarction [15]. Though the vast majority of SCN5A mutations elicit
impaired protein structure, common promoter or intronic single nucleotide polymorphisms of
the SCN5A gene can also associate with arrhythmia and sudden cardiac death [16–19].
Mutations and common polymorphic variants of the type 2 ryanodine receptor, a heart-spe-
cific sarcoplasmic reticulum calcium release channel, have also been implicated in certain car-
diac electrophysiological disorders such as catecholaminergic polymorphic ventricular
tachycardia and familial arrhythmogenic ventricular dysplasias [20–22] and sudden cardiac
death.
Though first described as a neuron-specific gene governing neuronal signaling and synaptic
plasticity, the nitric oxide synthase 1 adaptor protein (NOS1AP) has also been shown to modu-
late the intracellular calcium homeostasis in cardiomyocytes [23]. In light of this, it is not sur-
prising that polymorphic variants of the gene are associated with long QT syndrome and
ensuing fatal arrhythmias [24, 25] as well as increased cardiovascular mortality among patients
taking calcium channel blockers [26].
Myocardial hypertrophy, fibrosis and arterial wall remodeling are governed chiefly by mem-
bers of the TGFβ signaling pathway. In accordance with this, pathological roles have been
ascribed to variants of the transforming growth factor beta receptor 2 (TGFBR2) in aortic
aneurysm [27], Kawasaki disease [28] and sudden cardiac arrest against the background of cor-
onary artery disease [29]. Finally, polymorphisms of the type 2 adrenergic receptor, a well-
known obesity and metabolic syndrome susceptibility gene that mediates sympathetic activa-
tion in various tissues, have been implicated in increased mortality of patients with cardiovas-
cular disease [30–32] in general and sudden cardiac death in particular [31].
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The aim of the present case-control study was to find genetic polymorphisms that might be
independent and universal predictors of sudden cardiac death. To this end, selected single
nucleotide polymorphisms occurring in the above mentioned candidate genes have been geno-
typed in a cohort of Hungarian patients who succumbed to different cardiovascular ailments.
Materials and Methods
Subjects
Buccal swabs from 360 victims of natural, cardiovascular death (66.7% male, mean age:
68.02 ± 14.45 years) were collected post mortem during autopsies at the Department of Foren-
sic and Insurance Medicine (N = 262) and the 1st Department of Pathology (N = 98) of the
Semmelweis University between Sept 2011 and Nov 2013. Regarding the circumstances of
death, 165 cases (45.8%) were witnessed, unexpected, ‘established SCDs’ occurring within an
hour of symptom onset: 28 in hospital, 17 in public institutions, 37 in ambulance and 83 in
urban public places. 195 unwitnessed cases (54.2%) occurred at home without obvious extra-
cardiac cause, within 24 hours of last being observed in good, symptom-free condition, there-
fore fulfilling the internationally acknowledged criteria of ‘probable SCD’ [33].
Buccal sampling was carried out within four days after death on the average. Morphological
inclusion criteria were valvular heart disease; myocardial hypertrophy, fibrosis, fatty degenera-
tion or atrophy; calcification or thrombus in the coronary arteries; moderate or severe athero-
sclerosis in other arteries; and embolism in the pulmonary arteries. The 10th revision of the
International Classification of Diseases (ICD) was used for categorizing the cause of death
(Table 1). Violent death cases and cases where cardiovascular complications were consequences
of underlying primary diseases (such as malignancies and pneumonias) were excluded from the
study. No clinical records or data on medication, smoking, lifestyle factors etc. were considered.
The age-matched control group comprised 300 non-related volunteers (39.3% male, mean
age: 65.75 ± 14.83 years) without any known cardiovascular disease. Buccal samples of the par-
ticipants were collected at the Institute of Psychology, Eötvös Loránd University, Budapest,
Hungary.
All case and control subjects were Caucasian whites from the administrative area of
Budapest.
SNP selection
Of a multitude of polymorphisms known to associate with SCD, five single nucleotide poly-
morphisms (SNPs) were selected from the candidate genes described in the Introduction.
Selection of marker SNPs was based on results of previous genetic studies (Table 2).
Table 1. Characterization of the case population according to ICD (International Classification of Diseases) diagnoses and gender distribution.
ICD Codes Total Males Females
N % N % N %
Acute myocardial infarction I210-249 34 9.5% 21 8.8% 13 10.8%
Chronic ischemic heart disease I250-259 228 63.3% 165 68.7% 63 52.5%
Pulmonary embolism I260-269 25 7.0% 13 5.4% 12 10.0%
Nonrheumatic valve disorders I340-359 7 1.9% 5 2.1% 2 1.7%
Myocardial degeneration and cardiomegaly I515-517 59 16.4% 31 12.9% 28 23.3%
Aortic aneurysm rupture or dissection I710-729 7 1.9% 5 2.1% 2 1.7%
360 100.0% 240 100.0% 120 100.0%
doi:10.1371/journal.pone.0132137.t001
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Genotyping
Handling of buccal samples and isolation of genomic DNA was performed essentially as
described elsewhere [35]. Two parallel samples were obtained and processed from each partici-
pant. Concentration of genomic DNA solutions was measured by the AccuBlue Broad Range
dsDNA Quantification kit (Biotium, Hayward, USA). Concentrations of DNA stock solutions
varied between 15–200 ng/mL. Indicators of DNA purity were acceptable (OD 260/280 ratios
were between 1.6–2.0 and OD 260/230 ratios varied between 2.0–2.2), and agarose gel electro-
phoretic assays revealed no significant fragmentation of genomic DNA.
1 μL samples from tenfold diluted stock solutions were used for genotyping.
Genotyping of selected single nucleotide polymorphisms (SNPs) was performed by a 7300
Real-Time PCR System (LifeTechnologies, USA) using commercially available TaqMan Geno-
typing Assays (Applied BioSystem, Foster City, USA), according to the manufacturer’s instruc-
tions. The following TaqMan assays were used: C_2084765_20 for the rs1042714 SNP in the
ADRB2 gene; C_1777074 for rs10494366 in NOS1AP; C_409886_10 for rs790896 in RYR2;
C_30666704_10 for rs11720524 in SCN5A and C_11907338_10 for rs9838682 in TGFBR2.
Statistical analyses
Chi-square test of SPSS 17.0 for Windows was used for assessing the Hardy-Weinberg equilib-
ria. A genotype-based logistic regression model adjusting for age and sex was used for case-
control analysis. The Bonferroni correction was used for multiple testing. The Alibaba 2.1 tran-
scription factor binding prediction software and the TRANSFAC database were employed for
in silico transcription factor binding analysis.
Ethics statement
The study protocol was designed in accordance with guidelines of the Declaration of Helsinki.
Written informed consent was provided by all members of the control group. In accordance
with the current Hungarian National Health Law (law No. CLIV/1997), however, there is no
need to obtain informed consent from deceased individuals or their close relatives for post mor-
tem investigations including DNA sampling and genotyping if the individual did not issue a
declaration prohibiting any post mortem investigations before his/her death. To our best
knowledge, none of the participants issued such written declarations that would have pre-
vented them from being enrolled in the study.
Table 2. Results from individual studies used for SNP selection in the present study.
Gene SNP and position Study Phenotype
SCN5A rs11720524 [C/G] intron
1
Albert et al; 2010 [18] Associated with cases of sudden and/or arrhytmic cardiac death in individuals of
European ancestry
RYR2 rs790896 [A/G] 30-UTR Ran et al; 2010 [22] Associated with sudden cardiac death in patients with chronic heart failure in Chinese
Han population
ADRB2 rs1042714 [C/G] exon 1 Kulminski et al; 2010
[32]
Associated with the incidence of myocardial infarction in Framingham Heart Study
Offspring cohort
TGFBR2 rs9838682 [A/G] intron
3
Tseng et al; 2009 [29] Associate with sudden cardiac arrest in Caucasian patients with coronary artery disease
NOS1AP rs10494366 [G/T] intron
1
Aarnoudse et al; 2007
[34]
Associated with the QT interval duration in Rotterdam Study cohort
HR = hazard ratio; OR = odds ratio.
doi:10.1371/journal.pone.0132137.t002
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The study design, the use of human samples and the above described consent procedure
were all approved by the Scientific and Research Ethics Committee of the National Medical
Research Council (ETT-TUKEB; permission number: ETT TUKEB-398/2013). Approval from
the Institutional Review Board (IRB) was not necessary as the IRB is subordinate to ETT-TU-
KEB; however, the local IRB has also been informed on the issue of the ethical permission.
Results
In order to find a genetic polymorphism that could be used as a universal predictor of cardiac
death risk, we set up an intentionally very heterogeneous cohort of subjects who died of differ-
ent cardiovascular illnesses as verified through autopsy. Table 1 demonstrates the stratification
of the case population according to death causes. Though the majority of patients deceased of
chronic myocardial ischemia, degeneration or hypertrophy, there were pronounced gender dif-
ferences, as twice as many women died of pulmonary embolism and myocardial degeneration,
while the diagnosis of chronic coronary heart disease was made more frequently among male
subjects.
To dispel concerns on the quality of DNA obtained from post mortem sampling, we per-
formed PCR-based genotyping of a well-known length polymorphism in the type 4 dopamine
receptor gene that had much been studied previously in our laboratory [36]. Control PCR
assays were run successfully on all post mortem samples, confirming that they were applicable
for genetic testing
Five candidate genes of cardiac death have been selected from the current literature and one
representative single nucleotide polymorphism from each gene was genotyped by quantitative
PCR using allele-specific TaqMan probes. Though the list of genotyped variants is far from
being comprehensive, the selected candidate genes are known to be critically involved in the
pathomechanisms of sudden cardiac death which encompass dysrhythmias (SCN5A), per-
turbed intracellular calcium signaling (RYR2 and NOS1AP), myocardial remodeling
(TGFBR2) and sympathetic activation (ADRB2). Accordingly, four SNPs analyzed in the pres-
ent study (in genes ADRB2, RYR2, SCN5A and TGFBR2) have reportedly been associated with
SCD (Table 2). The rs10494366 SNP in the NOS1AP gene showed strong association with car-
diovascular mortality and high hazard ratio in patients treated with dihydropyridine calcium
channel blockers. Here, we wished to address the issue whether this variant is associated with
cardiac death in an extended, more heterogeneous patient population. Importantly, all geno-
type frequencies were in Hardy-Weinberg equilibrium in both the control and case population,
and call rates were higher than 95% for each SNP investigated (data not shown).
Genotype distributions for each SNP in both populations as well as results of the case-con-
trol association study are presented in Table 3. Genotype frequencies were compared using a
logistic regression model-based multivariate analysis accounting for age and gender differences
between the case and control populations (Table 3). P values and odds ratios (OR) with confi-
dence intervals (CI) for all five polymorphisms are shown in Table 3. Our results revealed that
the CC genotype of the rs11720524 (G/C) SNP of the SCN5A gene occurred more frequently
in the cardiovascular death cohort compared to the control group (47.90% vs. 36.99%,
p = 0.019, OR = 1.351), while none of the other studied polymorphisms showed any significant
differences in this respect.
Due to performing multiple comparisons, the accepted level of significance was corrected to
avoid false positive results. After applying the stringent Bonferroni correction for multiple test-
ing (p = 0.01 [0.05/5] as 5 SNPs were studied) the effect of the CC allele turned out to be
slightly below the threshold of statistical significance.
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The heterogeneity of the case population prompted us to perform a post hoc sub-analysis to
figure out which case subgroup was responsible for the above effect. It turned out that the CC
genotype occurred significantly more frequently in patients with chronic ischemic heart disease
(p = 0.012, OR = 1.455) but not in the other patient subgroups (Table 4). As the statistical
strength of the association was fairly enhanced by eliminating cases other than chronic ische-
mic heart disease, and the other SCD cases did not associate with the variant at all (p = 0.277),
our data support the notion that the common rs11720524 CC variant is associated with
increased SCD risk in patients with ischemic cardiomyopathy only, but not with the risk of
SCD in general.
Discussion
Given the high incidence and mortality of cardiovascular diseases, several prospective investi-
gations have recently been initiated with the aim to identify genetic and epigenetic markers
that predispose to cardiac death. Most association studies published so far have focused on a
clinically well-characterized subgroup of patients to uncover genetic variants in key candidate
Table 3. Case-control analysis of allele distributions.
Gene dbSNP No. alleles control case 95% CI 95% CI
N frequency N frequency p OR* lower upper
ADRB2 rs1042714 CC 106 36.68 132 37.18 0.868 1.020 0.810 1.283
CG 133 46.02 161 45.35
GG 50 17.30 62 17.46
NOS1AP rs10494366 GG 40 14.34 50 14.62 0.625 1.061 0.836 1.347
GT 129 46.24 160 46.78
TT 110 39.43 132 38.60
RYR2 rs790896 AA 56 18.86 65 18.31 0.945 1.008 0.801 1.269
AG 141 47.47 173 48.73
GG 100 33.67 117 32.96
SCN5A rs11720524 CC 108 36.99 171 47.90 0.019 1.351 1.050 1.737
CG 149 51.03 155 43.42
GG 35 11.99 31 8.68
TGFB2 rs9838682 AA 31 10.88 49 13.84 0.999 1.000 0.786 1.272
AG 139 48.77 144 40.68
GG 115 40.35 161 45.48
*OR = odds ratio; CI = conﬁdence intervals.
Table 4. Association of the SCN5A rs11720524 CC genotype with specific death causes in the case population.
Cause of death 95% CI 95% CI
p OR lower upper
acute myocardial infarction 0.198 1.468 0.818 2.633
chronic ischemic heart disease (IHD) 0.012 1.455 1.088 1.947
pulmonary embolism 0.790 1.093 0.569 2.099
nonrheumatic valve disorders 0.515 1.504 0.440 5.136
myocardial degeneration and cardiomegaly 0.939 1.017 0.661 1.565
aortic aneurysm rupture or dissection 0.188 2.701 0.616 11.854
non-IHD death cases 0.277 1.201 0.863 1.671
doi:10.1371/journal.pone.0132137.t004
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genes [8, 12, 14, 15, 18, 19, 22–25]. Here we selected five broadly studied SNPs which are
reportedly associated with certain forms of cardiac death and addressed the issue whether any
of these genetic markers are of general and independent predictive value in assessing the risk of
sudden cardiac death. In line with that, a particularly heterogeneous cohort of cardiac death
victims was investigated irrespective of additional factors including co-morbidities, smoking
and medication. Importantly, cardiac death victims were included on a random basis, without
any bias, from individuals autopsied at the institutions specified above.
Post mortem DNA sampling for genetic studies is a rare but not unusual procedure, and
there are reports claiming that the integrity of DNA in soft tissues is maintained even at ambi-
ent temperatures for several days after death [37]. Corpses involved in our study were refriger-
ated at 4°C before autopsy, and the quality of genomic DNA was carefully checked by
spectrophotometry, agarose gel electrophoresis and control PCR assays.
Our results revealed that CC variant of the rs11720524 [C/G] intronic polymorphism in the
SCN5A gene is associated with sudden cardiac death, but the association did not prove to be
statistically significant upon correction for multiple testing. This fact prompted us to assume
that there must be a more specific association between the gene variant and one (or some) of
the SCD subgroups. To clarify this issue, a post hoc analysis was performed that shed light on a
significant association of the CC genotype with the chronic ischemic heart disease cohort. The
other SCD cohorts did not show association with this variant either alone or in combination
(Table 4). Moreover, attenuation of the statistical power of the association by inclusion of the
non-ischemic cohorts (p = 0.012 vs. 0.019, OR = 1.351 vs. 1.455) also supported the conclusion
that the CC variant is associated with elevated SCD risk in chronic ischemic heart disease only
but not with SCD in general.
The lack of statistical association of SCD in any individual non-ischemic cohorts with the
gene variant might be attributable to the fact that sample sizes in these cohorts were very small,
i. e. not commensurate to those in the chronic ischemic group that made out nearly two third
of our SCD samples. A replication of the present study with bigger sample sizes might help elu-
cidate this issue.
The direction of the effect of the rs11720524 SNP is similar to that observed in two previous
studies. Albert et al. [18] described for the first time an association between the rs11720524 C
allele and arrhythmogenic and ischemic sudden cardiac death (p = 0.0005, OR = 1.30). In their
prospective study, 536 sudden cardiac death cases among US whites were included under very
rigorous inclusion criteria (cardiac arrest occurred within 1 hour of symptom onset as docu-
mented by medical or next-of-kin reports), and cardiac risk factors such as smoking, diabetes,
hypertension, hypercholesterolemia and family history were meticulously included in their sta-
tistical analysis. In our study, we included both established and probable ischemic cardiac
death cases, and no cardiac risk factors were known or considered. This difference as well as
the smaller sample size (N = 360) and the fact that they used an allele-wise conditional logistic
regression analysis might explain why we obtained less significant association between the ana-
lyzed polymorphism and SCD. On the other hand, it is to note that our effect size (OR = 1.455)
is outstandingly high for a common gene variant.
The predictive value of the same polymorphism has also been addressed by Son et al. [19]
in the Korean population where—in contrast to Caucasian people—the C variant is the minor
allele. Despite that, they found that the allele frequency of the C allele was twice as high in ven-
tricular arrhythmia-based sudden cardiac death cases as in the control population. Although
their results lack any statistical significance due to extremely small sample sizes (N = 14,
p = 0.25, OR = 2.13), it confers further support on our notion that the predictive value of the
C allele might be extended to other specific causes of sudden cardiac death if larger cohorts
were analyzed.
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The functional significance of the rs11720524 polymorphism remains to be elucidated. Nev-
ertheless, our in silico analysis revealed that the presence of the protective G allele creates a
DNA binding site for the POU domain containing transcription factor Oct-1. Though this
binding site is localized in intron 1 of the gene, it is not uncommon that transcription factors
are recruited to intronic regulatory sequences to confer enhanced transcription levels [38]. In
light of that, it is tempting to speculate that SCN5A expression levels might be lower in patients
harboring the CC genotype, and reduced SCN5A promoter activities have already been
reported to predispose to arrhythmogenic conductivity disorders such as longer PR and QRS
durations [39, 40]. This speculative assumption could explain the specific association of the CC
variant with increased SCD frequency just in chronic ischemic heart disease. Hypoxia induced
myocardial fibrosis is arrhythmogenic [3–5], and low SCN5A expression levels would further
promote the emergence of life-threatening ventricular arrhythmias.
Furthermore, one cannot exclude the possibility that genetic variants of the SCN5A gene
might influence expression levels via modulation of DNA methylation as proposed by Park
et al. recently [16]. Last but not least, the rs11720524 marker SNP might be genetically coupled
to other, functionally more important polymorphisms of the gene. To clarify this issue, a more
detailed genotyping of several polymorphisms covering the 5’ and 3’ regulatory regions of the
SCN5A gene should be performed.
Though the rest of investigated polymorphisms have previously been shown to associate
with specific forms of sudden cardiac death [22, 26, 27, 30 – 32], we could not recapitulate
these results in our highly heterogeneous case population probably due to low sample size.
Taken together, limitations of the study include the relatively small sample size, lack of rep-
lication on an independent case population, and lack of data on the impact of the rs11720524
alleles on gene expression. A more detailed analysis of other SCN5A polymorphisms should
also be performed.
The major strength of the study presented here is demonstration that the homozygous CC
genotype of the SCN5A rs11720524 SNP is significantly associated with SCD in patients
afflicted by chronic ischemic heart disease.
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